A Two-Step Screening, Measurement of HbA1c in Association with FPG, May Be Useful in Predicting Diabetes by Nomura, Kyoko et al.
A Two-Step Screening, Measurement of HbA1c in
Association with FPG, May Be Useful in Predicting
Diabetes
Kyoko Nomura
1*, Kazuo Inoue
2, Kimihiko Akimoto
3
1Teikyo University School of Medicine, Department of Hygiene and Public Health, Tokyo, Japan, 2Teikyo University School of Medicine, Department of Community
Medicine, Tokyo, Japan, 3Yuport, Medical Checkup Center, Tokyo, Japan
Abstract
Backgrounds: We compared the usefulness of fasting plasma glucose (FPG), or hemoglobin A1c (HbA1c), or both in
predicting type 2 diabetes.
Methods: This retrospective cohort study investigated 9,322 Japanese adults (4,786 men and 4,536 women), aged 19–
69 yrs, free of diabetes at baseline. Usefulness was assessed by predictive values (PV), sensitivity, specificity, and the area
under the receiver operating characteristic curve (AUROC) maximised under the best cut-off point.
Results: During the average 6 years of follow-up, 221 men (4.6%) and 92 women (2%) developed diabetes. The best cut-off
points for FPG (i.e., 5.67 mmol/l for men and 5.5 mmol/l for women) gave excellent AUROC, and the highest positive PV
(13% for men and 9% for women) in predicting diabetes. In high risk subjects with FPG 6.1–6.9 mmol/l, 119 men (26.8%)
and 39 women (28.3%) developed diabetes. Under the best cut-off points of FPG 6.39 mmol/l and A1c 5.8, AUROC and
positive PV for FPG slightly decreased indicating FPG became less useful and were statistically indistinguishable from those
for HbA1c in men. In fact, HbA1c was the most useful in women: HbA1c of 6.0% gave the highest positive likelihood ratio of
2.74 and larger AUROC than did FPG. Although AUROC for HbA1c was acceptable and indistinguishable from that for the
combined use, HbA1c had higher specificity and positive LR than did the combined use.
Conclusions: This study demonstrated that FPG was the most useful to predict diabetes in the general population.
However, in subjects with FPG 6.1–6.9 mmol/l, FPG became less useful and diagnostic performance of FPG was
indistinguishable from that of HbA1c in men whereas HbA1c was the most useful in women. Thus, a two-step screening,
measurement of HbA1c in association with FPG, may be useful in predicting diabetes.
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Introduction
The prevalence of type 2 diabetes is increasing at an alarming
rate. Current projections suggest that the absolute number of cases
worldwide may double over the next two decades [1]. Diabetes
causes long-term complications affecting the eyes, kidneys, and the
nervous system and leads to the development of micro- and
macro-vascular diseases. The speed of this progression is rapid;
people with newly diagnosed diabetes may already have
retinopathy. Therefore, early detection and intervention in
diabetes is now considered one of the most important public
health agendas.
Fasting plasma glucose (FPG) is a simple, easy, inexpensive, and
widely available to general population and has been most
frequently used to identify subjects at high risk of diabetes.
Hemoglobin A1c (HbA1c), an indirect measure of mean blood
glucose over the previous 2–3 months, does not require fasting,
and is more reproducible than FPG [2]. The 2-h plasma glucose
after oral glucose tolerance test (OGTT) is also useful to identify
subjects at impaired glucose tolerance. However, the OGTT is not
common in clinical practice, because it may be difficult to perform
and where the cost and demands on participants’ time may be
excessive [3].
Due to the recent advancement of HbA1c measurement, the
American Diabetes Association (ADA) report in 2009 [2]
advocated that, the diagnosis of diabetes may be conveniently
based on A1c$6.5%. However, the results of previous studies
have been inconsistent between A1c and FPG as to which test
yields better screening/predicting performance [4–11]. The
inconsistency is mainly due to the following two reasons. First,
these previous studies used methodologically two different models,
either a prognostic model or a diagnostic model or both. The
former usually estimates the risk of developing a disease outcome
(i.e., the odds ratio, or alternatively, the rate ratios or hazard ratio)
whereas the latter discriminates subjects with the disease state from
those without and typically uses receiver operating characteristic
(ROC) curves. Because the number of an odds ratio has little
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two different models might have caused the inconsistent results.
Second, among the studies that used diagnostic models, the
evaluation was typically based on the efficacy measures such as
sensitivity, specificity, and ROC and paid less attention to positive
predictive values. Positive PV which increases as prior probability
of disease (i.e., prevalence) increases is a powerful indicator of
usefulness of a test [13]. In this study, using a diagnostic model, we
investigated positive PV as well as the efficacy measures and
compared usefulness of three screening tests of FPG, A1c, and the
combined use in general population and high risk individuals with
FPG 6.1–6.9 mmol/l (110–125 mg/dl).
Methods
The data was obtained from those who received the complete
medical check-up at the Japan Post affiliated health centre. The
complete medical check-up offers comprehensive cancer screening
which is not covered by the annual health check-ups enforced by
law. Those who underwent the medical check-ups were nearby
residents, workers related to the Japan Post, and policy holders of
postal life insurance provided by the Japan Post.
In this study we set the 4-year baseline period to be between
April 1998 and March 2002 and the 4-year follow-up period
between April 2002 and March 2006. Study subjects were those
who took the check-up at both the baseline period and follow-up
period, yielding 11,129 persons. Further, among subjects at
baseline, we excluded those who already developed diabetes
including 129 subjects with known diabetes, 410 subjects with
FPG$7 mmol/l, and 140 subjects with HbA1c$6.5%. In
addition, 715 elderly subjects aged 70 years and above were
excluded because a large-scale epidemiological study reported that
older age was significantly associated with having a higher HbA1c
level even among healthy individuals [14]. Finally, after we
excluded those whose follow-up period was 2 years or shorter,
9,322 Japanese adults (4,786 males, 51%) aged 19–69 years
became our study subjects for analyses.
In accordance with the Private Information Protection Law,
information that might identify subjects was safeguarded by the
Medical Checkup Center. This study was approved by the review
board of Yuport Medical Checkup Center and a written informed
consent for anonymous participation in epidemiological research
was obtained at every evaluation.
All procedures were performed using the same protocols during
the baseline and follow-up periods, including blood tests. Height
and weight were measured to calculate body mass index (BMI).
Blood pressure was measured by trained nurses using a
sphygmomanometer. Blood samples were obtained after overnight
fasting and analyzed at the Center’s laboratory. Triglycerides and
total and high-density lipoprotein (HDL) cholesterol were
measured using enzymatic methods (reagents supplied by Daiichi
Pure Chemicals, Tokyo, Japan). FPG and HbA1c were measured
using a Toshiba TBA-40FR auto analyzer (Toshiba Medical
Systems, Tokyo, Japan). Plasma glucose was measured using the
hexokinase-G6PD method (Denka Seiken, Niigata, Japan). HbA1c
was measured using the latex immuno-agglutinin method
(Determiner hemoglobin HbA1c; Kyowa Medex, Tokyo, Japan).
Comparison of the Japan Diabetes Society primary standard
material using an assay by the Anchor Laboratory of the National
Glycohemoglobin Standardization Program (NGSP) in the USA
revealed that the NGSP value (%)=JDS value (%)+0.4% [15].
Thus, our results were reported using converted NGSP values.
NGSP alignment is equivalent to the Diabetes Control and
Complications Trial alignment.
Diabetes was defined according to the 2010 American Diabetes
Association (ADA) criteria [16]: FPG$7.0 mmol/l, HbA1c values
$6.5%, or both, or treatment by oral antidiabetic drugs or insulin.
We defined high risk subjects as those with 6.1–6.9 mmol/l (110–
125 mg/dl).
Usefulness of a test was assessed by sensitivity, specificity,
likelihood ratios (LR), AUROC, and PV. The best cutoff point
known to be closest to the upper left-hand corner of the ROC
curve was determined where the test characteristics were
maximized. In a trade-off between sensitivity and specificity,
sensitivity was prioritized over specificity as much as possible for
the purpose of screening. Positive/negative PV is defined as the
proportion of those with a positive/negative test result who
actually has/does not have disease. When the pretest probability of
disease is high, positive PV increases [13]. This means, the
increase of positive PV indicates that a larger number of people at
risk will be detected and thus is used as a measure of usefulness.
Basic characteristics of study subjects are presented as mean and
standard deviation (SD) or median with inter-quartile range (IQR)
according to the distribution of each variable. Age-adjusted ROC
curves were drawn by logistic regression models, with FPG and
HbA1c treated as continuous variables. Regression lines were
separately fitted between the newly identified diabetics and
HbA1c, FPG, and the combination of FPG and HbA1c [8].
The age-adjusted AUROC and the 95% CI were calculated by
the Delong method. According to Hosmer and Lemeshow [17], an
AUROC value between 0.7 and 0.8 is considered ‘‘acceptable,’’
and one between 0.8 and 0.9 ‘‘excellent’’ discrimination.
Test characteristics were calculated using SAS software (version
9.12, Cary, NC, USA), and the AUROC was calculated using
STATA software (version 11, College Station, TX, USA).
Results
During the follow-up period (average of 6 years), 221 men
(4.6%) and 92 women (2%) in the entire subject population
developed type 2 diabetes. Among subjects whose FPG level was
between 6.1–6.9 mmol/l during the baseline period, 119 men
(26.8%) and 39 women (28.3%) developed type 2 diabetes. Table 1
shows baseline characteristics in the entire subject population and
subjects with FPG 6.1–6.9 mmol/l according to gender. In the
entire subject population, mean FPG was statistically higher in
men than in women and mean HbA1c was higher in women than
in men. In subjects with FPG of 6.1–6.9 mmol/l, mean HbA1c
was higher in women than in men but FPG was not statistically
different between gender.
The best cut-off points, closest to the left upper corner of
AUROC were 5.67 mmol/l for FPG and 5.5% for HbA1c in men
(Figure 1A), and 5.5 mmol/l for FPG and 5.7% for HbA1c in
women (Figure 1B). In subjects with FPG 6.1–6.9 mmol/l, the cut-
off points were 6.39 mmol/l for FPG and 5.8% for HbA1c in men
(Figure 1C) and 6.39 mmol/l for FPG and 6.0% for HbA1c in
women (Figure 1D). The AUROC for FPG (0.86, 95%CI:0.84–
0.89 for men and 0.90, 95%CI:0.87–0.94 for women, Table 2) was
statistically greater than that for HbA1c in both men and women
(0.82, 95%CI:0.79–0.85 for men and 0.84, 95%CI:0.80–0.89 for
women, Table 2). However in subjects with FPG of 6.1–
6.9 mmol/l, the AUROC for HbA1c (0.79, 95%CI: 0.71–0.88,
Table 3) was statistically greater than that for FPG (0.70, 95%CI:
0.61–0.79, Table 3) in women.
Table 2 shows test characteristics maximized under the best cut-
off point in the entire subject population. In men, the combined
use of FPG and A1c had the largest AUROC (0.90, 95%CI:0.88–
0.92). However, the AUROC for FPG had also excellent
Usefulness of FPG and HbA1c for Diabetes
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a.
All Subjects with FPG 6.1–6.9 mmol/l
Men (n=4786) Women (n=4536) p Men (n=444) Women (n=138) p
Age(yrs) 50611 53610 ,.0001 54685 7 67 ,.0001
Body Mass Index (kg/m2) 23.662.8 22.263.0 ,.0001 24.862.9 24.163.9 0.887
Fasting plasma glucose (mmol/l) 5.4160.49 5.1060.46 ,.0001 6.3960.24 6.3760.24 0.450
A1c(%) 5.3660.39 5.3860.40 0.008 5.6860.39 5.8060.40 0.002
HDL cholesterol (mmol/l) 1.3860.35 1.6860.38 ,.0001 1.3360.31 1.5460.37 ,.0001
Triglycerides{ (mmol/l) 1.28 (0.92, 1.84) 0.91 (0.68, 1.27) ,.0001 1.51 (1.09, 2.07) 1.20 (0.89, 1.70) ,.0001
Total cholesterol (mmol/l) 5.1260.87 5.3760.92 ,.0001 5.3360.93 5.6061.00 0.006
Uric acid(mmol/l) 0.1060.02 0.0860.02 ,.0001 0.1160.02 0.0960.02 ,.0001
Systolic blood pressure (mmHg) 126617 120618 ,.0001 133618 132615 0.880
Diastolic blood pressure (mmHg) 77611 72611 ,.0001 81611 79610 0.209
aPresented as mean 6SD.
{Triglycerides is presented with median (25%, 75%) because of the skewed distribution.
doi:10.1371/journal.pone.0036309.t001
Figure 1. The best cut-off points shown in the receiver operating characteristic curve, conducted in Japan, 1998–2006.
Abbreviations:A1c, HbA1c; FPG, fasting plasma glucose, fpgplusA1c, the combined use of FPG and HbA1c. Figure 1A. Men (n=4786). Figure 1B.
Women (n=4536). Figure 1C. Men with 6.1–6.9 mmol/l (n=444). Figure 1D. Women with 6.1–6.9 mmol/l (n=138).
doi:10.1371/journal.pone.0036309.g001
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higher specificity (0.73, 95%CI: 0.72–0.75) and positive PV (0.13,
95%CI: 0.12–0.15) compared to those for the combined use (0.51,
95%CI: 0.49–0.52 and 0.09, 95%CI: 0.08–0.10, respectively).
This indicates that FPG alone than the combined use is more
useful in men.
In women, both FPG alone and the combined use had the
largest AUROC (0.90, 95%CI: 0.87–0.94 vs. 0.92, 95%CI: 0.89–
0.95). But among there two, FPG alone had higher specificity
(0.82, 95%CI: 0.81–0.84) and positive PV (0.09, 95%CI: 0.07–
0.11) compared to those for the combined use (0.66, 95%CI: 0.64–
0.67 and 0.05, 95%CI: 0.04–0.07, respectively). This indicates that
FPG alone than the combined use is more useful also in women.
Table 3 shows test characteristics maximized under the best cut-
off point in high risk subjects with FPG 6.1–6.9 mmol/l. In men,
positive PV, and AUROC as well as other efficacy measures
except for specificity and negative LR were not statistically
different among the three screening tests of FPG, HbA1c and the
combined use. The combined use had the least negative LR of 0.4
indicating that the negative result of both FPG and HbA1c did not
exclude diabetes with sufficient certainty. In addition, the
combined use had the least specificity. Thus, FPG or HbA1c
alone was thought to be more useful than the combined use in
men in this group.
In women, both HbA1c alone and the combined use had the
largest AUROC (0.79, 95%CI: 0.71–0.88 and 0.84, 95%CI: 0.77–
0.91, respectively). But HbA1c had higher specificity (0.75,
95%CI: 0.65–0.83) and positive LR (2.74, 95%CI: 1.84–4.08),
than those for the combined use (0.48, 95%CI: 0.37–0.58 and
1.76, 95%CI: 1.43–2.16, respectively). This indicates that HbA1c
alone is the most useful in women.
Discussion
To summarize our results, FPG was the most useful screening
test in predicting diabetes in the entire study population, but in
high risk subjects with FPG of 6.1–6.9 mmol/l, FPG became less
useful and diagnostic performance of FPG was indistinguishable
from that of HbA1c in men whereas HbA1c was the most useful in
women.
Previously, several studies based on AUROC analyses have
reported that the combined use of HbA1c and FPG had the
highest efficacy for diabetes [7–9]. Indeed, this study agreed that
the combined use had the largest AUROC across the strata but
demonstrated that AUROC for FPG also had excellent discrim-
ination in whole men and women. In addition, FPG had the
highest positive PV among three comparisons. This indicates that
FPG is the most useful test in whole population because it can
detect a larger number of individuals with diabetes. Thus, our
Table 2. Test Characteristics (95% Confidence Interval) maximized under the Best Cut-off Point in the entire subject population.
Sen Spec PPV NPV LR+ LR2
Age-adjusted
AUROC
Men (n=4786, diabetes: 4.6%, cut off points: FPG 5.67 mmol/l, A1c 5.5)
FPG 0.85 (0.80–0.89) 0.73 (0.72–0.75) 0.13 (0.12–0.15) 0.99 (0.98–0.99) 3.20 (2.97–3.44) 0.20 (0.15–0.28) 0.86 (0.84–0.89)
HbA1c 0.84 (0.79–0.89) 0.63 (0.62–0.65) 0.10 (0.09–0.11) 0.98 (0.98–0.99) 2.29 (2.14–2.46) 0.25 (0.18–0.34) 0.82 (0.79–0.85)
FPG plus HbA1c 0.97 (0.94–0.99) 0.51 (0.49–0.52) 0.09 (0.08–0.10) 0.99 (0.99–1.00) 1.98 (1.91–2.06) 0.05 (0.02–0.12) 0.90 (0.88–0.92)
Women (n=4536, diabetes: 2.0%, cut off points: FPG 5.5 mmol/l, A1c 5.7)
FPG 0.85 (0.75–0.91) 0.82 (0.81–0.84) 0.09 (0.07–0.11) 0.99 (0.99–1.00) 4.81 (4.33–5.37) 0.19 (0.11–0.30) 0.90 (0.87–0.94)
HbA1c 0.76 (0.66–0.84) 0.76 (0.66–0.84) 0.06 (0.05–0.08) 0.99 (0.99–0.99) 3.16 (2.79–3.59) 0.32 (0.22–0.45) 0.84 (0.80–0.89)
FPG plus HbA1c 0.94 (0.86–0.97) 0.66 (0.64–0.67) 0.05 (0.04–0.07) 0.99 (0.99–0.99) 2.73 (2.55–2.92) 0.10 (0.05–0.22) 0.92 (0.89–0.95)
Abbreviations: CI, Confidence Interval; FPG, Fasting Plasma Glucose; LR+, Positive Likelihood Ratio; LR2, Negative Likelihood Ratio; NPV, Negative Predictive Value; PPV,
Positive Predictive Value; Sen, Sensitivity; Spec, Specificity.
doi:10.1371/journal.pone.0036309.t002
Table 3. Test Characteristics (95% Confidence Interval) maximized under the Best Cut-off Point in Subjects with FPG 6.1–
6.9 mmol/l.
Sen Spec PPV NPV LR+ LR2
Age-adjusted
AUROC
Men (n=444, diabetes: 26.8%, cut off points: FPG 6.39 mmol/l, A1c 5.8)
FPG 0.65 (0.56–0.74) 0.60 (0.55–0.66) 0.38 (0.31–0.45) 0.83 (0.77–0.87) 1.65 (1.37–1.99) 0.57 (0.44–0.74) 0.67 (0.60–0.72)
HbA1c 0.63 (0.54–0.72) 0.64 (0.58–0.69) 0.39 (0.32–0.46) 0.83 (0.77–0.87) 1.74 (1.42–2.12) 0.58 (0.46–0.74) 0.68 (0.62–0.73)
FPG plus HbA1c 0.83 (0.75–0.89) 0.42 (0.37–0.48) 0.35 (0.29–0.40) 0.87 (0.81–0.92) 1.44 (1.27–1.63) 0.40 (0.27–0.60) 0.71 (0.66–0.77)
Women (n=138, diabetes: 28.3%, cut off points: FPG 6.39 mmol/l, A1c 6.0)
FPG 0.62 (0.45–0.76) 0.64 (0.53–0.73) 0.40 (0.28–0.54) 0.81 (0.70–0.89) 1.69 (1.18–2.43) 0.60 (0.40–0.91) 0.70 (0.61–0.79)
HbA1c 0.69 (0.52–0.82) 0.75 (0.65–0.83) 0.52 (0.38–0.66) 0.86 (0.77–0.92) 2.74 (1.84–4.08) 0.41 (0.25–0.66) 0.79 (0.71–0.88)
FPG plus HbA1c 0.92 (0.78–0.98) 0.48 (0.37–0.58) 0.41 (0.31–0.52) 0.94 (0.82–0.98) 1.76 (1.43–2.16) 0.16 (0.05–0.49) 0.84 (0.77–0.91)
Abbreviations: CI, Confidence Interval; FPG, Fasting Plasma Glucose; LR+, Positive Likelihood Ratio; LR2, Negative Likelihood Ratio; NPV, Negative Predictive Value; PPV,
Positive Predictive Value; Sen, Sensitivity; Spec, Specificity.
doi:10.1371/journal.pone.0036309.t003
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the most useful test.
Our results that measurement of HbA1c in association with
FPG is useful in predicting diabetes are consistent with the results
of recent studies [18–20]. A study conducted by Inoue et al. [18]
diagnosed diabetes in 10,042 subjects using FPG and HbA1c, and
reported that diabetes diagnosis with FPG levels between 5.6 and
6.9 mmol/L and an elevated HbA1c between 5.5 and 6.4% led to
substantial improvements in the risk of progression to diabetes.
Another study conducted by Heianza, et al. [19] investigated 6241
subjects and reported that predictive value of progression to
diabetes assessed by HbA1c 5.7–6.4% substantially increased in
those with impaired fasting glucose (IFG). These studies indicate
that in high-risk individuals, diagnostic criteria based on FPG
criteria are relatively insensitive, but HbA1c measurement
improves the sensitivity of screening. Furthermore, a meta-analysis
[20] reported that dysglycaemic individuals were at a roughly five-
to-ten times increased risk of diabetes compared with individuals
without IFG or impaired glucose tolerance.
Our study had limitations that should be discussed. First, there
were 21,885 subjects in total who participated in the complete
medical check-ups. Among these, we only included those who
underwent the check-ups at both baseline and follow-up periods,
which might have caused selection bias. Nevertheless, when
comparing baseline characteristics between those who did and did
not participate in the follow-up, the mean of age (52.9 vs. 51.8 y/
o), BMI (22.9 vs. 22.8 kg/m2), FPG levels (5.27 vs. 5.28 mmol/l),
and HbA1c (4.97 vs. 4.95%) were actually comparable between
the two groups. Second, FPG and HbA1c in this study were
assessed only at baseline and follow-up. The inter- and intra-
coefficient variations in glucose values may have caused some
random misclassification in glucose categories and thereby
influenced our results. Nevertheless, glucose levels in healthy
individuals do not fluctuate as observed in diabetic subjects [21].
Furthermore, because our subjects had blood tests right before
they underwent gastrofiberscopy and abdominal ultrasound,
measurement of FPG in the fasting state was highly reliable.
Third, the present study did not use OGTT as a basis for
exclusion, which might influence the results. Given that, according
to a previous report, FPG alone failed to diagnose 30% of patients
with diabetes who were diagnosed by a 2-h plasma glucose test
[22], some individuals in our study might have had diabetes at
inclusion. Thus, the results of our study require careful attention to
interpret the findings. Forth, in high risk men with 6.1–6.9 mmol/
l, the optimal screening test is indeterminate between FPG and
HbA1c. These two measures had in fact not very high sensitivity
(0.65 for FPG and 0.63 for HbA1c) which means that the number
of false negative was relatively high. In this regard, we have
mandatory health checkup system in Japan where any adults must
take periodical glycemic checkup: for every worker by Industrial
Safety and Health Act and for the elderly and house wives by
Health Promotion Act. Thus, the person who had negative results
but diabetes may be more likely to be screened in the subsequent
health checkup. Fifth, the result of this study is based on Japanese
population and thus may be different in other ethnic groups.
Despite these limitations, the result of this study suggests that
FPG may be the most useful in the general population, whereas
HbA1c may be more useful in subjects with high risk individuals
with 6.1–6.9 mmol/l. Our findings may conflict with the ADA
report in 2009 because it advocates that the screening diabetes is
based on HbA1c measurement and a repeat HbA1c test should be
done for confirmation in asymptomatic patients [3]. Takahashi et
al. [23] investigated 16,313 healthy Japanese and reported that the
cumulative diabetes incidence at 3 years for those with baseline
HbA1c of less than 5.0%, 5.0–5.4%, and 5.5–5.9% was 0.05%,
0.05%, and 1.2%, respectively. The authors further reported that
among those with an HbA1c under 6.0%, rescreening at intervals
shorter than 3 years identified few individuals (,1% or less) with
an HbA1c $6.5%. Thus, this study does not contradict the result
of our study suggesting that routine measurement of HbA1c in the
general population may not be recommended. Furthermore,
Malkani and Mordes [24] suggested that in choosing a diagnostic
test for diabetes, the limitations of glucose measurement and
HbA1c must be understood; for example, HbA1c assay may not
be available in parts of the world and is its greater expense
compared to FPG.
In summary, measurement of FPG in the fasting state may be
the most useful to predict diabetes in general population.,
However, our study demonstrated that among high risk subjects
with 6.1–6.9 mmol/l, FPG was less useful and the diagnostic
performance of FPG was indistinguishable from that of HbA1c in
men whereas HbA1c was found to be more useful than FPG in
women. Thus, the results of our study suggest a two-step screening
in predicting diabetes; firstly the use of FPG is recommended in
overall general population and then in high risk subjects with 6.1–
6.9 mmol/l, measurement of HbA1c in association with FPG may
be useful in predicting diabetes. The results of our study may
provide important insight into how to use limited resources for the
best health intervention. Given that FPG is less expensive than
HbA1c and the local performance of the HbA1c assay is not
always available, it is suggested that FPG may be used as a first
screening approach, with HbA1c being used for further screening
for those at high risk of diabetes. However, it should be noted that
screening strategy should provide safety net to screen those with
false negative at the initial screening by the subsequent screening.
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